title: Deep transcriptome profiling of ovarian cancer cells using next-generation sequencing approach.
abstract: The next-generation sequencing technology allows identification and cataloging of almost all mRNAs, even those with only one or a few transcripts per cell. To understand the chemotherapy response program in ovarian cancer cells at deep transcript sequencing levels, we applied two next-generation sequencing technologies to study two ovarian chemotherapy response models: the in vitro acquired cisplatin-resistant cell line model (IGROV-1-CP and IGROV1) and the in vivo ovarian cancer tissue resistant model. We identified 3,422 signatures (2,957 genes) that are significantly differentially expressed between IGROV1 and IGROV-1-CP cells (P < .001). Our database offers the first comprehensive view of the digital transcriptomes of ovarian cancer cell lines and tissues with different chemotherapy response phenotypes.
authors.affiliation: Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang Province, P R China.
authors.forename: Lisha
authors.initials: L
authors.lastname: Li
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Yu
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Lou
authors.forename: Bingding
authors.initials: B
authors.lastname: Huang
authors.forename: Biaoyang
authors.initials: B
authors.lastname: Lin
mesh_terms: D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods*; D006801:Humans; D008967:Molecular Biology / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
chemical_list: D002945:Cisplatin